Amicoumacin A induces cancer cell death by targeting the eukaryotic ribosome

Irina V Prokhorova1, Kseniya A Akulich2,3, Desislava S Makeeva2,3

  • 1Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM U964, CNRS UMR7104, Université de Strasbourg, 67404, Illkirch, France.

Scientific Reports
|June 15, 2016
PubMed

Insights

Amicoumacin A antibiotic inhibits translation by targeting bacterial ribosomes, affecting elongation in yeast and mammalian systems. Cancer cells show higher susceptibility, suggesting potential for new drug development.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Antimicrobial Research

Background:

  • Amicoumacin A is an antibiotic targeting bacterial ribosomes.
  • It influences translocation and creates an additional binding interface between ribosomal RNA and messenger RNA.
  • The drug's binding site involves universally conserved ribosomal RNA nucleotides.

Purpose of the Study:

  • To investigate amicoumacin A's inhibitory effects on translation in yeast and mammalian systems.
  • To determine the structural basis of amicoumacin A binding to ribosomes.
  • To assess the differential toxicity of amicoumacin A towards cancerous versus non-cancerous cells.

Main Methods:

  • Inhibition assays in yeast and mammalian translation systems.
  • Cryo-electron microscopy to determine the structure of the amicoumacin A-yeast ribosome complex.
  • Toxicity measurements using human cancer and non-cancerous cell lines.

Main Results:

  • Amicoumacin A was shown to inhibit translation elongation in both yeast and mammalian systems.
  • The structure of amicoumacin A complexed with yeast ribosomes was determined at 3.1 Å resolution.
  • Human cancer cell lines exhibited greater susceptibility to amicoumacin A inhibition compared to non-cancerous cells.

Conclusions:

  • Amicoumacin A effectively inhibits translation elongation in eukaryotic systems.
  • The structural data provides insights into the mechanism of action.
  • The differential toxicity suggests potential for developing targeted cancer therapies.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
14
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K